BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32776290)

  • 1. Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
    Heeke AL; Xiu J; Elliott A; Korn WM; Lynce F; Pohlmann PR; Isaacs C; Swain SM; Vidal G; Schwartzberg LS; Tan AR
    Breast Cancer Res Treat; 2020 Nov; 184(2):265-275. PubMed ID: 32776290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.
    Park W; Chen J; Chou JF; Varghese AM; Yu KH; Wong W; Capanu M; Balachandran V; McIntyre CA; El Dika I; Khalil DN; Harding JJ; Ghalehsari N; McKinnell Z; Chalasani SB; Makarov V; Selenica P; Pei X; Lecomte N; Kelsen DP; Abou-Alfa GK; Robson ME; Zhang L; Berger MF; Schultz N; Chan TA; Powell SN; Reis-Filho JS; Iacobuzio-Donahue CA; Riaz N; O'Reilly EM
    Clin Cancer Res; 2020 Jul; 26(13):3239-3247. PubMed ID: 32444418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications.
    Toh M; Ngeow J
    Oncologist; 2021 Sep; 26(9):e1526-e1537. PubMed ID: 34021944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive analysis of POLE/POLD1 genomic alterations in colorectal cancer.
    Mosalem O; Coston TW; Imperial R; Mauer E; Thompson C; Yilma B; Bekaii-Saab TS; Stoppler MC; Starr JS
    Oncologist; 2024 May; ():. PubMed ID: 38776551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution.
    Aleksakhina SN; Ivantsov AO; Imyanitov EN
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.
    Boscolo Bielo L; Repetto M; Crimini E; Belli C; Setola E; Parma G; Fusco N; Barberis M; Guerini Rocco E; Marra A; Colombo N; Curigliano G
    Oncologist; 2024 May; ():. PubMed ID: 38716772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kataegis in clinical and molecular subgroups of primary breast cancer.
    Veerla S; Staaf J
    NPJ Breast Cancer; 2024 Apr; 10(1):32. PubMed ID: 38658600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Pathology of Breast Tumors: Diagnostic and Actionable Genetic Alterations.
    Ross DS; Pareja F
    Clin Lab Med; 2024 Jun; 44(2):255-275. PubMed ID: 38821644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive molecular profiling identifies actionable biomarkers for patients from Thailand and the United Arab Emirates with advanced malignancies.
    Dawood S; Natarajan V; Danchaivijitr P
    Front Oncol; 2024; 14():1374087. PubMed ID: 38800398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CK2-HTATSF1-TOPBP1 signaling axis modulates tumor chemotherapy response.
    Guo Q; Zhao J; Li Y; Zhang C; Shen X; Liu L; Yang Z; Ma S; Qin Y; Shi L
    J Biol Chem; 2024 May; 300(6):107377. PubMed ID: 38762174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational inference of cancer-specific vulnerabilities in clinical samples.
    Jang K; Park MJ; Park JS; Hwangbo H; Sung MK; Kim S; Jung J; Lee JW; Ahn SH; Chang S; Choi JK
    Genome Biol; 2020 Jun; 21(1):155. PubMed ID: 32600395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
    Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
    BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
    Bodily WR; Shirts BH; Walsh T; Gulsuner S; King MC; Parker A; Roosan M; Piccolo SR
    PLoS One; 2020; 15(9):e0239197. PubMed ID: 32997669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 and PALB2 in a Messy Breakup.
    Her J; Bunting SF
    Cancer Res; 2020 Oct; 80(19):4044-4045. PubMed ID: 33008804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological Features and Outcomes in Individuals with Breast Cancer and ATM, CHEK2, or PALB2 Mutations.
    Bergstrom C; Pence C; Berg J; Partain N; Sadeghi N; Mauer C; Pirzadeh-Miller S; Gao A; Li H; Unni N; Syed S
    Ann Surg Oncol; 2021 Jun; 28(6):3383-3393. PubMed ID: 32996020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer.
    Abraham JP; Magee D; Cremolini C; Antoniotti C; Halbert DD; Xiu J; Stafford P; Berry DA; Oberley MJ; Shields AF; Marshall JL; Salem ME; Falcone A; Grothey A; Hall MJ; Venook AP; Lenz HJ; Helmstetter A; Korn WM; Spetzler DB
    Clin Cancer Res; 2021 Feb; 27(4):1174-1183. PubMed ID: 33293373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function.
    Khoury K; Lynce F; Barac A; Geng X; Dang C; Yu AF; Smith KL; Gallagher C; Pohlmann PR; Nunes R; Herbolsheimer P; Warren R; Srichai MB; Hofmeyer M; Asch F; Tan M; Isaacs C; Swain SM
    Breast Cancer Res Treat; 2021 Feb; 185(3):863-868. PubMed ID: 33400034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer.
    Borden BA; Baca Y; Xiu J; Tavora F; Winer I; Weinberg BA; Vanderwalde AM; Darabi S; Korn WM; Mazar AP; Giles FJ; Crawford L; Safran H; El-Deiry WS; Carneiro BA
    Mol Cancer Ther; 2021 Jan; 20(1):183-190. PubMed ID: 33087512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort.
    Mathioudaki A; Ljungström V; Melin M; Arendt ML; Nordin J; Karlsson Å; Murén E; Saksena P; Meadows JRS; Marinescu VD; Sjöblom T; Lindblad-Toh K
    Sci Rep; 2020 Nov; 10(1):19304. PubMed ID: 33168853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.